Pancreatic Cancer Research

ResearcherIstituto Nazionale Tumori IRCCS "Fondazione G. Pascale"Active in the last 2 years

Antonio Avallone

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6188-5664; OpenAlex author ID A5088304855. Sources: ClinicalTrials.gov.

Their work

Papers
11 (first author 0, last author 1)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
34
Papers, trials and grants by year

2017: 2 papers · 2018: none · 2019: none · 2020: 1 paper · 2021: 3 papers · 2022: 2 papers · 2023: 2 papers, 1 trial · 2024: 1 paper

Papers 11

  1. Randomized phase 2 study of valproic acid combined with simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic pancreatic adenocarci… Last author DOI 10.1186/s12885-024-12936-w↗
  2. Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA… Co-author DOI 10.1007/s00280-023-04585-w↗
  3. Risk Assessment and Pancreatic Cancer: Diagnostic Management and Artificial Intelligence. Co-author DOI 10.3390/cancers15020351↗
  4. HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation. Co-author DOI 10.1186/s13046-022-02295-4↗
  5. Correction to: HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation. Co-author DOI 10.1186/s13046-022-02324-2↗
  6. Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort. Co-author DOI 10.1016/j.esmoop.2020.100032↗
  7. Clinical Phase I/II Study: Local Disease Control and Survival in Locally Advanced Pancreatic Cancer Treated with Electrochemotherapy. Co-author DOI 10.3390/jcm10061305↗
  8. A Multicenter Randomized Controlled Prospective Study to Assess Efficacy of Laparoscopic Electrochemotherapy in the Treatment of Locally Advanced Pancreatic Ca… Co-author DOI 10.3390/jcm10174011↗
  9. Magnetic resonance imaging in the assessment of pancreatic cancer with quantitative parameter extraction by means of dynamic contrast-enhanced magnetic resonan… Co-author DOI 10.1177/1756284819885052↗
  10. Gemcitabine mono-therapy versus gemcitabine plus targeted therapy in advanced pancreatic cancer: a meta-analysis of randomized phase III trials. Co-author DOI 10.1080/0284186x.2017.1288922↗
  11. Nab-Paclitaxel and Gemcitabine in Advanced Pancreatic Cancer: The One-year Experience of the National Cancer Institute of Naples. Co-author DOI 10.21873/anticanres.11539↗

Trials 1

  1. Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients Principal investigator NCT05821556↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Alfredo Budillon · 3 shared papers, 1 shared trial, 2022–2024 · strength 1.00
  2. Raffaéle Palaia · 4 shared papers, 2020–2023 · strength 0.47
  3. Vincenza Granata · 4 shared papers, 2020–2023 · strength 0.47
  4. Antonella Petrillo Petrillo · 4 shared papers, 2020–2023 · strength 0.47
  5. Francesco Izzo · 4 shared papers, 2020–2023 · strength 0.47
  6. Maria Serena Roca · 3 shared papers, 2022–2024 · strength 0.42
  7. Marina Macchini · 3 shared papers, 2021–2024 · strength 0.39
  8. Giampaolo Tortora · 3 shared papers, 2021–2024 · strength 0.39
  9. Michele Reni · 3 shared papers, 2021–2024 · strength 0.39
  10. Salvatore Tafuto · 3 shared papers, 2017–2021 · strength 0.26
  11. Umberto Peretti · 2 shared papers, 2021–2023 · strength 0.23
  12. Giulia Orsi · 2 shared papers, 2021–2023 · strength 0.23
  13. Guido Giordano · 2 shared papers, 2021–2023 · strength 0.23
  14. Ilario Giovanni Rapposelli · 2 shared papers, 2021–2023 · strength 0.23
  15. Monica Niger · 2 shared papers, 2021–2023 · strength 0.23
  16. Lisa Salvatore · 2 shared papers, 2021–2023 · strength 0.23
  17. Michèle Milella · 2 shared papers, 2021–2023 · strength 0.23
  18. Stefano Cascinu · 2 shared papers, 2021–2023 · strength 0.23
  19. Francesca Foschini · 1 shared paper, 2024 · strength 0.16
  20. Claudia Fuchs · 1 shared paper, 2024 · strength 0.16
  21. Mario De Bellis · 1 shared paper, 2023 · strength 0.15
  22. Alessandro Ottaiano · 2 shared papers, 2017 · strength 0.14
  23. Anna Maria Militello · 1 shared paper, 2023 · strength 0.14
  24. Letizia Procaccio · 1 shared paper, 2023 · strength 0.14
  25. Elisa Giommoni · 1 shared paper, 2023 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.